Which two medications have the highest risk of agranulocytosis and aplastic anemia?

Enhance your preparation for the PMHNP Certification Exam with Georgette's resources. Delve into multiple-choice questions and detailed explanations to ensure you're ready for success. Boost your study efficiency and exam confidence today!

Multiple Choice

Which two medications have the highest risk of agranulocytosis and aplastic anemia?

Explanation:
The highest risk of both agranulocytosis and aplastic anemia is associated with clozapine and carbamazepine. Clozapine stands out among antipsychotics for its well-known and serious risk of agranulocytosis, which is why it requires regular blood monitoring (WBC and absolute neutrophil count) and careful dose management or discontinuation if counts drop. Carbamazepine also carries a significant risk of agranulocytosis and, though less common, aplastic anemia, especially in the early months of treatment. The other two drugs—lurasidone and olanzapine—have far lower hematologic toxicity profiles, so the combination with the greatest risk of these severe blood disorders is clozapine paired with carbamazepine.

The highest risk of both agranulocytosis and aplastic anemia is associated with clozapine and carbamazepine. Clozapine stands out among antipsychotics for its well-known and serious risk of agranulocytosis, which is why it requires regular blood monitoring (WBC and absolute neutrophil count) and careful dose management or discontinuation if counts drop. Carbamazepine also carries a significant risk of agranulocytosis and, though less common, aplastic anemia, especially in the early months of treatment. The other two drugs—lurasidone and olanzapine—have far lower hematologic toxicity profiles, so the combination with the greatest risk of these severe blood disorders is clozapine paired with carbamazepine.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy